Recently, Shanghai Hantong Medical Technology Co., Ltd. completed tens of millions of yuan in angel round financing. This round of financing was led by Tongchuang Weiye, with joint participation from Haimaide Venture Capital and Yanxitang Fund. The raised funds will be used for the construction of interventional ultrasound research and development platform, and the research and production of related products.
For most hypertensive patients, the main ways to stabilize blood pressure are lifestyle intervention and hypertension drug treatment, but both of these methods require lifelong persistence and compliance. The emergence of renal artery sympathetic nerve ablation (RDN) has broken this treatment bottleneck. Blood pressure is controlled by removing the sympathetic nerve of the renal artery. Its mechanism of action has been confirmed by a large number of clinical data. At present, there are various energy platforms at home and abroad competing for RDN products. Ultrasound energy has the clinical advantages of deeper penetration, larger 360° coverage area, and almost no damage to the vascular intima, so ultrasound is considered to be a better energy choice for RDN.
Hantong Medical focuses on active interventional products, especially in the field of vascular interventional ultrasound, and has launched a fully self-developed ultrasound energy platform. The first product is used for renal artery ultrasonic ablation to treat hypertension, covering multiple core technologies such as host, algorithm, catheter, and ultrasonic transducer.
The company has also laid out the next-generation ultrasound energy platform, which will combine ablation therapy and ultrasound diagnosis to achieve the clinical advantages of targeted ablation and real-time monitoring of ablation effects. As a universal technology for denervation and ablation, the ultrasonic energy platform can be expanded to treat pulmonary hypertension, diabetes, heart failure, chronic obstructive pulmonary disease and many other fields, and has a huge market space.
At the same time, Hantong Medical is also actively deploying the pulmonary embolism market. Pulmonary embolism is one of the three major cardiovascular fatal diseases. At present, there is still a blank in the field of interventional surgical equipment for pulmonary embolism in China. The intravascular ultrasound-assisted drug thrombolysis system and catheter developed by Hantong Medical, combined with microbubbles, reduces the use of thrombolytic drugs by more than 95%, has an extremely low recurrence rate of thrombus, and at the same time, the catheter with a smaller size is easy to operate. No blood loss and no damage to the pulmonary artery.
Dr. Zhao Wanjin, founder and CEO of Hantong Medical, said: “Thanks to the investors for their trust and strong support, Hantong Medical will continue to do a good job in independent innovation and research and development of core technologies and products, and accelerate the promotion of products to the clinical stage to benefit as soon as possible. Patients. In the future, we will further deploy product lines around clinical needs, and at the same time build active technology platforms such as energy and consumables around the pan-vascular field, create a rich portfolio of interventional disease diagnosis and treatment products, and continue to promote innovation.”
Xi Yanbin, partner of Cochuang Weiye Beijing Medical Fund, said: “RDN products are one of the few products that are at the same starting line at home and abroad, and have a huge patient base and market space. URDN based on ultrasonic energy has already shown good clinical results. value. However, interventional ultrasound involves a series of core technologies such as acoustics, materials, software and hardware, and algorithms, which need to be tackled, and there are high technical barriers. Hantong Medical is a leading interventional ultrasound platform company in China, and the founding team has many years of technology in this field Accumulated, it is expected to achieve breakthroughs in multiple directions such as renal artery ultrasonic ablation, catching up with international giants. In addition, as a platform technology, ultrasonic energy can be expanded to more clinical fields and combined with diagnosis, creating a new era for society and patients. Great value.”
Zhai Jingbo, partner of Haimide Venture Capital, said: “We are very optimistic about the combination of R&D and sales of the founding team, especially the founding team is both classmates and has continuous entrepreneurial experience. Hantong Medical was founded and incubated in the Yanxitang Incubator, and the founding team showed With strong execution ability, many technical problems were quickly overcome, and the basic finalization of the product was completed. We will continue to incubate and support outstanding entrepreneurs, and look forward to seeing Hantong continue to innovate in the tens of billions of RDN market , complete catching up and surpassing.”
media reports
Arterial Network Arterial Network Investment Community Entrepreneurship State
related events
- “Hantong Medical” completed tens of millions of yuan in angel round financing, led by Tongchuang Weiye2022-12-08
- “Qihui Biology” completed tens of millions of yuan in Series A financing, led by Weidu Venture Capital 2022-12-06
- Changde Medical completed tens of millions of yuan in angel round financing, led by Legend Capital2022-10-24
- Non-vascular interventional brand ” Carben Medical” completed tens of millions of pre-A+ rounds of financing2022-08-25
- “Kona Medical” received nearly 100 million yuan in B2 round financing, led by dry financing skills2022-07-28
This article is transferred from: https://readhub.cn/topic/8lzq7MAeSut
This site is only for collection, and the copyright belongs to the original author.